Welcome to our dedicated page for Artisan Acqu SEC filings (Ticker: PRENW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Artisan Acqu's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Artisan Acqu's regulatory disclosures and financial reporting.
Prenetics Global Limited reports a Board change and a sharpened strategic focus on its IM8 health and longevity brand. Director Andy Cheung resigned effective February 16, 2026, with the company stating his departure was not due to any disagreement. As part of its renewed focus, Prenetics has discontinued any future purchases of Bitcoin or other cryptocurrencies effective December 4, 2025.
The company appointed Dr. Darshan Shah, a longevity expert and health-tech CEO, as an independent director effective February 16, 2026, and he will also serve on key Board committees. Prenetics highlights IM8’s rapid growth, noting the brand surpassed $100 million in annualized recurring revenue within 11 months and is now sold in more than 30 countries.
Prenetics Global Limited reports a Board change and a sharpened strategic focus on its IM8 health and longevity brand. Director Andy Cheung resigned effective February 16, 2026, with the company stating his departure was not due to any disagreement. As part of its renewed focus, Prenetics has discontinued any future purchases of Bitcoin or other cryptocurrencies effective December 4, 2025.
The company appointed Dr. Darshan Shah, a longevity expert and health-tech CEO, as an independent director effective February 16, 2026, and he will also serve on key Board committees. Prenetics highlights IM8’s rapid growth, noting the brand surpassed $100 million in annualized recurring revenue within 11 months and is now sold in more than 30 countries.
Prenetics Global Limited completed the sale of its 35% equity interest in Insighta to Tencent for total cash proceeds of $70 million, providing a substantial, non‑dilutive cash inflow and strengthening its balance sheet.
As of February 15, 2026, Prenetics reported total adjusted liquidity of $171.1 million, including $99.3 million in cash and cash equivalents, $29.3 million in financial assets at fair value through profit or loss, $7.3 million in escrow balances and $35.2 million in Bitcoin, while operating with zero outstanding debt. Management frames this divestiture as the final major step in a strategic shift to focus on IM8, its fast‑growing consumer health and longevity brand, supporting global expansion and product innovation. The company plans to discuss its financial position and outlook with fourth‑quarter and full‑year 2025 results, scheduled for pre‑market release on February 18, 2026.
Prenetics Global Limited completed the sale of its 35% equity interest in Insighta to Tencent for total cash proceeds of $70 million, providing a substantial, non‑dilutive cash inflow and strengthening its balance sheet.
As of February 15, 2026, Prenetics reported total adjusted liquidity of $171.1 million, including $99.3 million in cash and cash equivalents, $29.3 million in financial assets at fair value through profit or loss, $7.3 million in escrow balances and $35.2 million in Bitcoin, while operating with zero outstanding debt. Management frames this divestiture as the final major step in a strategic shift to focus on IM8, its fast‑growing consumer health and longevity brand, supporting global expansion and product innovation. The company plans to discuss its financial position and outlook with fourth‑quarter and full‑year 2025 results, scheduled for pre‑market release on February 18, 2026.